Krill Oil Raises Omega-3 Blood Levels 50% Higher Than Fish Oil in RCT
A 12-week randomized trial finds krill oil boosts plasma EPA and DHA roughly 1.5× more than equivalent fish oil doses.
Summary
A double-blind randomized trial of 72 healthy adults compared krill oil and fish oil supplementation at equal omega-3 doses (1.1 g/day) over 12 weeks. Krill oil, which delivers EPA and DHA as phospholipids, raised plasma EPA and DHA approximately 1.5-fold more than fish oil, which delivers them as triglycerides. Women absorbed EPA more efficiently than men, showing 1.5-fold greater increases at 12 weeks. Carriers of the APOE4 gene — associated with Alzheimer's risk and altered fat metabolism — showed notably high responses to both supplements, though differences from non-carriers were not statistically significant. The findings suggest people with higher omega-3 needs may reach target plasma levels with lower krill oil doses than fish oil doses.
Detailed Summary
Omega-3 fatty acids EPA and DHA are among the most widely studied nutrients for cardiovascular, cognitive, and inflammatory health. Yet despite decades of research, debate persists about whether the chemical form of omega-3 supplements — phospholipid-bound (krill oil) versus triglyceride-bound (fish oil) — meaningfully affects how much actually reaches the bloodstream.
This double-blind randomized controlled trial from Université de Sherbrooke enrolled 72 healthy adults (53 women, 19 men) matched for age and BMI. Participants received either krill oil or fish oil providing an identical 1.1 g/day of omega-3s for 12 weeks. Blood samples were drawn at baseline and at weeks 1, 2, 4, and 12, with plasma fatty acid concentrations measured by gas chromatography.
The headline result is clear: krill oil produced approximately 1.5-fold higher increases in both plasma EPA and DHA compared to fish oil, a statistically significant difference. This advantage is attributed to the phospholipid structure of krill oil, which may enhance intestinal absorption and incorporation into blood lipids. A notable secondary finding is that women absorbed EPA more efficiently than men — showing 1.5-fold greater EPA gains at 12 weeks — suggesting sex-based differences in omega-3 metabolism deserve clinical attention.
APOE4 carriers showed striking absolute increases (3-fold for EPA, 1.6-fold for DHA) after supplementation with either oil, though the difference from non-carriers did not reach statistical significance, likely due to the small number of APOE4 carriers in the sample.
For clinicians and health-conscious individuals, the practical implication is significant: achieving therapeutic omega-3 plasma levels may require lower doses of krill oil than fish oil, potentially improving compliance and cost-effectiveness. Caveats include the abstract-only availability of full data, the relatively small and predominantly female sample, and the single 1.1 g/day dose tested.
Key Findings
- Krill oil raised plasma EPA ~1.5× more than equal-dose fish oil over 12 weeks.
- Krill oil raised plasma DHA ~1.5× more than fish oil, regardless of APOE4 status.
- Women showed 1.5-fold greater EPA absorption than men at the 12-week mark.
- APOE4 carriers showed large omega-3 increases (3× EPA, 1.6× DHA), but differences from non-carriers were non-significant.
- Lower krill oil doses may suffice to reach target plasma omega-3 levels versus fish oil.
Methodology
Double-blind RCT with 72 healthy adults randomized to krill oil or fish oil at 1.1 g/day omega-3s for 12 weeks. Plasma fatty acids measured at 5 time points via gas chromatography-flame ionization detection. Participants were matched for age and BMI; statistical models assessed treatment-by-time, sex-by-time, and APOE4-by-treatment interactions.
Study Limitations
This summary is based on the abstract only, as the full text is not open access, so complete methodological details and data tables could not be reviewed. The sample was small (n=72) and predominantly female, limiting generalizability, particularly for sex- and APOE4-stratified analyses. Only a single dose (1.1 g/day) was tested, so dose-response relationships and higher therapeutic doses remain unexplored.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.